Inhalational Drug Delivery in Pulmonary Aspergillosis

Kaur, Ranjot; Kaur, Ripandeep; Singh, Charan; Kaur, Swaran; Goyal, Amit K.; Singh, Kamalinder K.; Singh, Bhupinder

doi:10.1615/critrevtherdrugcarriersyst.2018025781

Cited by 15 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, pulmonary drug delivery offers the advantage of positioning the bioactive molecule in direct contact with the pathological lung epithelia, thus ensuring a rapid onset of the therapeutic response. High local drug concentrations may be easily obtained by pulmonary administration with a concomitant increase in the pharmacological effect but without the side effects elicited by other administration routes [57]. As previously reported, fenretinide has shown In vivo activity against A. fumigatus infection.…”

Section: Unmet Needs In Fungal Infectionsmentioning

confidence: 73%

Retinoids in Fungal Infections: From Bench to Bedside

et al. 2021

View full text Add to dashboard Cite

Retinoids—a class of chemical compounds derived from vitamin A or chemically related to it—are used especially in dermatology, oncohematology and infectious diseases. It has been shown that retinoids—from their first generation—exert a potent antimicrobial activity against a wide range of pathogens, including bacteria, fungi and viruses. In this review, we summarize current evidence on retinoids’ efficacy as antifungal agents. Studies were identified by searching electronic databases (MEDLINE, EMBASE, PubMed, Cochrane, Trials.gov) and reference lists of respective articles from 1946 to today. Only articles published in the English language were included. A total of thirty-nine articles were found according to the criteria. In this regard, to date, In vitro and In vivo studies have demonstrated the efficacy of retinoids against a broad-spectrum of human opportunistic fungal pathogens, including yeast fungi that normally colonize the skin and mucosal surfaces of humans such as Candida spp., Rhodotorula mucilaginosa and Malassezia furfur, as well as environmental moulds such as Aspergillus spp., Fonsecae monofora and many species of dermatophytes associated with fungal infections both in humans and animals. Notwithstanding a lack of double-blind clinical trials, the efficacy, tolerability and safety profile of retinoids have been demonstrated against localized and systemic fungal infections.

show abstract

Section: Unmet Needs In Fungal Infectionsmentioning

confidence: 73%

Retinoids in Fungal Infections: From Bench to Bedside

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The in vitro antimicrobial data on fungal isolates unravelled the potential of developed nanosystems to target the most prominent strain of fungal lung infections viz., Aspergillus fumigates responsible for causing more than 60% of the lung infections [8], followed by other Aspergillus and Candida species.…”

Section: Discussionmentioning

confidence: 99%

“…The currently available antifungal regimen is restricted to oral and parenteral routes only, which limits the therapeutic availability of drugs in the lungs owing to limitations of poor solubility, low permeability and rapid clearance of drug [8]. Pulmonary route offers myriad advantages like faster onset of action, localized non-invasive therapy, circumnavigation of the first-pass effect and reduced systemic side effects [9].…”

Section: Introductionmentioning

confidence: 99%

Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Incidence of pulmonary aspergillosis is rising worldwide, owing to an increased population of immunocompromised patients. Notable potential of the pulmonary route has been witnessed in antifungal delivery due to distinct advantages of direct lung targeting and first-pass evasion. The current research reports biomimetic surface-active lipid-polymer hybrid (LPH) nanoparticles (NPs) of voriconazole, employing lung-specific lipid, i.e., dipalmitoylphosphatidylcholine and natural biodegradable polymer, i.e., chitosan, to augment its pulmonary deposition and retention, following nebulization. Results The developed nanosystem exhibited a particle size in the range of 228–255 nm and drug entrapment of 45–54.8%. Nebulized microdroplet characterization of NPs dispersion revealed a mean diameter of ≤ 5 μm, corroborating its deep lung deposition potential as determined by next-generation impactor studies. Biophysical interaction of LPH NPs with lipid-monolayers indicated their surface-active potential and ease of intercalation into the pulmonary surfactant membrane at the air-lung interface. Cellular viability and uptake studies demonstrated their cytocompatibility and time-and concentration-dependent uptake in lung-epithelial A549 and Calu-3 cells with clathrin-mediated internalization. Transepithelial electrical resistance experiments established their ability to penetrate tight airway Calu-3 monolayers. Antifungal studies on laboratory strains and clinical isolates depicted their superior efficacy against Aspergillus species. Pharmacokinetic studies revealed nearly 5-, 4- and threefolds enhancement in lung AUC, Tmax, and MRT values, construing significant drug access and retention in lungs. Conclusions Nebulized LPH NPs were observed as a promising solution to provide effective and safe therapy for the management of pulmonary aspergillosis infection with improved patient compliance and avoidance of systemic side-effects.

show abstract

“…Particularly, the use of nanocarriers in delivering antifungal agents through the pulmonary route has been investigated due to their ability to improve the stability and bioavailability of antifungal agents. Antifungal agents encapsulated in nanocarriers can be delivered to the lungs through dry powder inhalers (DPI) in the form of dry powders and nebulizers in the form of solutions or suspensions [31]. More details on DPI and nebulized formulations will be discussed in the next section.…”

Section: Pulmonary Delivery Of Antifungal Agentsmentioning

confidence: 99%

“…The Aspergillus conidia are able to penetrate deep into the lungs and hence, the antifungal drug particles also needed to penetrate as deeply as the inhaled conidia. Further, the powder blends in DPI can either be a mixture of micronized drug with coarse carrier particles such as lactose, mannitol and sucrose or drug particles encapsulated in nanocarrier particles [31,33].…”

Section: Dry Powder Inhaler Formulationsmentioning

confidence: 99%

A Critical Review on Emerging Trends in Dry Powder Inhaler Formulation for the Treatment of Pulmonary Aspergillosis

et al. 2020

View full text Add to dashboard Cite

Pulmonary aspergillosis (PA), a pulmonary fungal infection caused by Aspergillus spp., is a concern for immunocompromised populations. Despite substantial research efforts, conventional treatments of PA using antifungal agents are associated with limitations such as excessive systemic exposure, serious side effects and limited availability of the therapeutics in the lungs for an adequate duration. To overcome the limitations associated with the conventional regimens, pulmonary delivery of antifungal agents has become a focal point of research because of the superiority of local and targeted drug delivery. Dry powder inhalers and nebulized formulations of antifungal agents have been developed and evaluated for their capability to effectively deliver antifungal agents to the lungs. Moreover, progress in nanotechnology and the utilization of nanocarriers in the development of pulmonary delivery formulations has allowed further augmentation of treatment capability and efficiency. Thus, the following review provides an insight into the advantages and therapeutic potential of the utilization of nanocarriers in pulmonary delivery of antifungal agents for the treatment of PA. In addition, discussions on formulation aspects and safety concerns together with the clinical and regulatory aspects of the formulations are presented, which suggest the possibility and desirability of utilization of nanocarriers in the treatment of PA.

show abstract

Inhalational Drug Delivery in Pulmonary Aspergillosis

Cited by 15 publications

References 0 publications

Retinoids in Fungal Infections: From Bench to Bedside

Retinoids in Fungal Infections: From Bench to Bedside

Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention

A Critical Review on Emerging Trends in Dry Powder Inhaler Formulation for the Treatment of Pulmonary Aspergillosis

Contact Info

Product

Resources

About